Navigation Links
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
Date:11/3/2008

ptember 30, 2008, Rigel had cash, cash equivalents and available for sale securities of $160.4 million, compared to $185.0 million as of June 30, 2008 and $108.3 million as of December 31, 2007. In February 2008, Rigel completed a public offering raising aggregate net proceeds of approximately $127.5 million.

"Data from our Phase 2a clinical trial of R788 in rheumatoid arthritis was recently presented by the principal investigator at the plenary session of the American College of Rheumatology," said James M. Gower, chairman and chief executive officer of Rigel. "We continue to be very pleased with the safety profile of R788 and expect to release data on the Phase 2b clinical trials in the second half of 2009," he added.

Clinical Update

R788

Rigel expects that R788 for rheumatoid arthritis will continue to be the primary clinical focus for Rigel. Two Phase 2b clinical trials are ongoing in rheumatoid arthritis, TASKi2 and TASKi3. Rigel expects TASKi2 to complete enrollment by the first quarter of 2009 and to have initial results by late summer 2009. Rigel also anticipates that initial results on TASKi3 will be available by late summer 2009.

Rigel expects to initiate a Phase 2 clinical trial for T-cell lymphoma within the next several months. The ongoing Phase 2 lymphoma clinical trial is continuing and is focused on diffuse large B-cell, follicular and other B- cell lymphomas, including chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). Rigel plans to present further results from this ongoing clinical trial at the American Society of Hematology (ASH) meeting in December 2008.

The exploratory Phase 2a clinical trial in immune thrombocytopenic purpura (ITP) is ongoing and we expect the results to be published in the next couple of months. Rigel has deferred initiating any further trials in ITP until a collaboration partner for R788 is in place.

Likewise, Rigel has deferred initiating a clinical trial
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
3. Rigel to Present at BIO CEO & Investor Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel to Present Research Programs at Scientific Conferences
6. Rigel to Present at BIO Investor Forum 2007
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
9. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
10. Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer
11. BMP Sunstone Announces Participation in November Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... an Irys™System by BGI , the ... enable comprehensive exploration of human structural variation (SV) and ... interest, including those where no reference exists. In addition, ... methods for multiplexing on the Irys System, enabling significantly ...
(Date:7/31/2014)... 31, 2014 Although RNA-Sequencing is ... first transcriptome-wide analyses appearing around 2008, RNA-Sequencing has ... RNA measurement. In the last several years, assays ... work with smaller input amounts, process degraded RNA, ... samples). On the bioinformatics side, there have been ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... is slowly getting over its shyness about asking for ... small business executives is learning more about how ... Research-Small Business Technology Transfer Conference at the Hilton ... mandated programs, one (SBIR) designed to foster small business ...
... Google advertisers should consider dayparting tactics and ... AdWords campaign. , ,Until recently, Google AdWords tactics ... creative, and geography. However, when Google began offering ... another way to control AdWord spending and optimize ...
... investors have fewer secrets these days, and they were ... executives during the National SBIR-STTR Conference. , ,In evaluating ... University of Wisconsin-Madison , they counseled technology start ... market advantage, and what each round of funding is ...
Cached Biology Technology:Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Getting the most from Google dayparts 2Getting the most from Google dayparts 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... biomass burning burning forests to create agricultural ... agriculture and wildfires figures into both climate ... release of a new study by Stanford University ... the degree of that contribution had never been ... paper published July 30 in the Journal ...
(Date:7/31/2014)... the roughly 156,000 gas stations across the United ... of underground gas storage tankscorrosion that could result ... source of drinking water. In recent years, field ... corroding gas storage tank components such as sump ... of gasoline-ethanol blends and the presence of bacteria, ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4NIST corrosion lab tests suggest need for underground gas tank retrofits 2
... common cancers could soon come from cutting-edge research into some ... on Sarcoma and GIST, to be held in Milan, Italy, ... the world,s leading experts will discuss exciting new science on ... deep skin tissues, nerves and the tissues around joints. ...
... Prostate-specific dietary supplements should not be taken during ... to increase the radiosensitivity of normal prostate cell ... a study in the March issue of the ... official journal of the American Society for Radiation ...
... 2010 The Society for Nutrition Education (SNE) ... and American Society for Nutrition (ASN) to publish ... Association, American Society for Nutrition, and Society for ... Older Adults," focusing on access to safe and ...
Cached Biology News:Spotlight on rare tumors in hunt for new cancer treatments 2Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Concentrated Applications: ELISA...
Biology Products: